Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Conor expands COSTAR II

This article was originally published in The Gray Sheet

Executive Summary

FDA approves Conor Medsystem's plan to expand enrollment of the COSTAR II U.S. pivotal trial of the CoStar cobalt chromium paclitaxel-eluting stent to 85 sites and 1,700 patients. An initial IDE for the trial was approved by FDA in March. The trial randomizes patients with single or multi-vessel de novo coronary lesions to receive either CoStar or Boston Scientific's Taxus paclitaxel-eluting stent. CoStar is available in Europe and India...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT022969

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel